ELC Group has appointed internationally acclaimed clinical pharmacologist Dr Siddharth Chachad as head of global clinical development and medical affairs.
A member of the UK Faculty of Pharmaceutical Medicine, Dr Chachad is an expert in the design and execution of preclinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr Siddharth’s extensive expertise covers all phases of clinical studies, including preclinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.
“The appointment of Dr Siddharth Chachad comes at a pivotal time for ELC Group,” said Marco Rubenstein, CEO of ELC Group. “Having been instrumental in the development of successful product registration strategies, I have no doubt that Dr Siddarth will prove an exceptional leader of our global clinical development and medical affairs team.”
Dr Chachad added: “I am excited to be joining ELC Group and bringing my experience of clinical development and medical affairs to what is already a world-class team in this area.”
A renowned speaker at numerous clinical research and pharmacovigilance conferences, Dr Chachad has authored over 25 publications.